Brief: Recursion Pharmaceuticals Enters Amendment To Master Agreement With Tempus On Sept 15, 2026 - SEC Filing
21/09/2026 14:08
BRIEF-Recursion Pharmaceuticals Enters Amendment To Master Agreement With Tempus On Sept 15, 2026 - SEC Filing Sept 21 (Reuters) - Recursion Pharmaceuticals, Inc. RXRX.O:
RECURSION PHARMACEUTICALS - ENTERS AMENDMENT TO MASTER AGREEMENT WITH TEMPUS ON SEPT 15, 2026 - SEC FILING
RECURSION PHARMACEUTICALS - EXTENDS AGREEMENT TERM FROM FIVE TO SIX YEARS - SEC FILING
RECURSION PHARMACEUTICALS - ELIMINATES CO'S RIGHT TO TERMINATE AGREEMENT FOR CONVENIENCE - SEC FILING
Source text: [ID:n0001601830-26-000112]
Further company coverage: RXRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Recursion Pharmaceuticals
See all newsBrief: Tempus And Recursion Extend Existing Data License Agreement And Enter New License Agreement For Recursion’S RNA Foundation Model
Brief: Recursion Pharmaceuticals Enters Amendment To Master Agreement With Tempus On Sept 15, 2026 - SEC Filing
Recursion Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Recursion Pharmaceuticals Q2 revenue misses estimates, cuts 2026 expense outlook
Brief: Recursion Pharmaceuticals Q2 Operating Revenue USD 7.303 Million Vs. IBES Estimate USD 11.9 Million